NASDAQ · Biotechnology · USD
Revelation Biosciences, Inc. (REVB) Stock Analysis
Revelation Biosciences, Inc. (REVB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
REVB Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.75
- Previous Close
- $0.47
- Day's Range
- 3.51–3.97
- 52-Week Range
- 3.08–40.60
- Volume
- 19.04K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.06
Valuation
- Market Cap
- $2.05M
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$8.91M
- Shares Outstanding
- 569.06K
- 1-Year Return
- −28.00%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 9.16K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, REVB closed at $3.60, −28.00% over 1 year.
Revelation Biosciences, Inc. (REVB) has a market capitalization of $2.05M.
In fiscal 2025, REVB reported revenue of $0.00.
REVB Stock Return by Calendar Year
Revelation Biosciences, Inc. (REVB) return since Nov 2020: what $10,000 became
- 1 year
- $10,000 $7,200
- −28.00%
- 5 years
- $10,000 $0.02
- −99.9998%
- Since Nov 2020
- $10,000 $0.02
- −99.9998%
If you had invested $10,000 in Revelation Biosciences, Inc. (REVB) at the close on November 17, 2020, the earliest close on record here, it would have been worth $0.02 at the close on October 21, 2026: −99.9998% in total, −89.25% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +12.50% |
| 2025 | −96.38% |
| 2024 | −96.93% |
| 2023 | −92.47% |
| 2022 | −98.14% |
| 2021 | +1.49% |
| 2020 (partial year) | +2.97% |
As of October 21, 2026.
REVB Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$8.91M | — |
| 2024 | $0.00 | −$15.04M | — |
| 2023 | $0.00 | −$120.25K | — |
| 2022 | $0.00 | −$10.83M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$9.07M | −$8.91M | — |
| 2024 | $0.00 | — | −$7.98M | −$15.04M | — |
| 2023 | $0.00 | — | −$8.66M | −$120.25K | — |
| 2022 | $0.00 | — | −$10.86M | −$10.83M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
YahooRevelation Biosciences Announces 1-For-7 Reverse Stock Split, Effective Oct. 20
BenzingaRevelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
BenzingaRevelation Biosciences (NASDAQ:REVB) Surges on Pipeline Progress Despite Q2 Earnings Miss
ChartMillRevelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
BenzingaRevelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B